49 results on '"Haas G.P."'
Search Results
2. 1398P Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES
3. Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES.
4. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
5. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.
6. The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
7. Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES
8. LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
9. Association of local progression with deterioration of urinary symptoms and occurrence of genitourinary adverse events (AEs) in nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Post hoc analysis of PROSPER
10. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.
11. Reply by Authors.
12. Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormonesensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial.
13. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
14. Impact of baseline disease volume and prior docetaxel therapy on PSA-related outcomes in patients with mHSPC receiving enzalu-tamide plus ADT.
15. Arches-the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): Post hoc analyses of high and low disease volume and risk groups.
16. LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC).
17. 1777P Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints
18. 1778P Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK
19. ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormonesensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups.
20. ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels.
21. Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormonesensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.
22. ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC) by prior local and systemic treatment.
23. ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups.
24. 691TiP A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study status
25. 635P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels
26. ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC) by prior local and systemic treatment
27. ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
28. 853P - ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
29. Global treatment patterns for late-stage prostate cancer: Updated results from ASPIRE-PCa
30. Enzalutamide in European and North American men participating in the AFFIRM trial
31. Enzalutamide in European and North American men participating in the AFFIRM trial
32. 2525 ASPIRE-PCa: Initial findings from a prospective, global observational study of men with late-stage prostate cancer
33. 747P - Global treatment patterns for late-stage prostate cancer: Updated results from ASPIRE-PCa
34. 583 UPDATING THE NOMOGRAM TO PREDICT INDOLENT PROSTATE CANCER TOWARDS MORE EXTENDED CONTEMPORARY BIOPSY SCHEMES
35. 1016 EXTENDED BIOPSIES ON AUTOPSY PROSTATES: STAGING OF MICROFOCAL CANCERS
36. Carcinogenicity of the N-hydroxy derivative of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, 2-amino-3,8-dimethyl-imidazo[4,5-f]quinoxaline and 3,2′-dimethyl-4-aminobiphenyl in the rat
37. Epidemology of High Grade Prostatic Intraepithelial Neoplasia
38. The Frequency of Carcinoma and Intraepithelial Neoplasia of the Prostate in Young Male Patients
39. N-Acetyltransferase expression and DNA binding of N-hydroxyheterocyclic amines in human prostate epithelium
40. Prevention of Hemorrhagic Cystitis Following Allogeneic Bone Marrow Transplant Preparative Regimens With Cyclophosphamide and Busulfan: Role of Continuous Bladder Irrigation
41. Intralesional Treatment of Established Murine Primary Renal Tumor With Interleukin-4: Localized Effect on Primary Tumor With no Impact on Metastases
42. Radiation-Induced Effects on Murine Kidney Tumor Cells: Role in the Interaction of Local Irradiation and Immunotherapy
43. The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.
44. The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.
45. The prevalence of prostatic intraepithelial neoplasia and latent carcinoma of the prostate in white and Afro-American males
46. Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin
47. Editorial: Strategies to Manage Prostate Cancer
48. P151 - Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer (BCR) following Radical Prostatectomy (RP) or Radiation Therapy (RT): EMBARK post hoc analysis
49. A0517 - Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.